



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number:

0 396 387 A3

12

EUROPEAN PATENT APPLICATION

21 Application number: 90304734.8

91 Int. Cl.⁵: A61K 47/48, C12N 15/62

22 Date of filing: 01.05.90

30 Priority: 05.05.89 US 348237

43 Date of publication of application:
07.11.90 Bulletin 90/45

84 Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

88 Date of deferred publication of the search report:
03.04.91 Bulletin 91/14

71 Applicant: RESEARCH DEVELOPMENT
FOUNDATION
402 North Division Street
Carson City Nevada 89703(US)

72 Inventor: Rosenblum, Michael G.
8801 North Rylander Circle
Houston, Texas 77071(US)
Inventor: Wellen, Clyde William
2121 Kirby Drive, No. 79
Houston, Texas 77019(US)

74 Representative: Wilkinson, Stephen John et al
c/o Stevens, Hewlett & Perkins 5 Quality
Court Chancery Lane
London WC2A 1HZ(GB)

54 A novel antibody delivery system for biological response modifiers.

57 The present invention provides a novel conjugate of an antibody with a biological response modifiers; delivery system which delivers biological response modifiers to target tissues and cells. The present invention also provides a method for treating diseases by administering antibody-biological response modifier conjugates.

For example, a monoclonal antibody conjugated to a lymphokine or cytokine, such as for example, TNF.

EP 0 396 387 A3



EP 90 30 4734
Page 1

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	US-A-4590071 (SCANNON P.J. ET AL) * the whole document *	1, 3, 8	A16K47/48 C12N15/62
X	GB-A-1564666 (MUN HON, N.G. ET AL) * the whole document *	1, 3, 4	
X	WO-A-8500974 (HYBRITECH) * the whole document *	1, 3, 4	
X	PROCEEDINGS OF AMERICAN ASSOCIATION FOR CANCER RESEARCH vol. 28, March 1987, ATLANTA, GEORGIA page 384 ZUCKERMAN, J.E. et al: "Preparation and biological activity of recombinant leukocyte interferon A[rIFN alpha A] conjugated to an antimelanoma murine monoclonal antibody [ZME-018]." * the whole document *	1-3, 8-10	
X	EP-A-305967 (CIBA-GEIGY) * the whole document *	1, 3, 4	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
X,P	EP-A-336631 (IMMUNOMEDICS) * the whole document *	1, 3, 4	A61K C12N A16K
X	NUCLEAR MEDICINE AND BIOLOGY vol. 16, no. 6, 1989, EXETER GB pages 625 - 627; SPITLER L.E. et al: "Therapy of metastatic malignant melanoma using xomazyme mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin." * the whole document *	1, 3, 8	
X,P	EP-A-350230 (RESEARCH AND DEVELOPMENT FOUNDATION) * the whole document *	1, 3, 8	
A,D	EP-A-184369 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) * the whole document *	1-13	
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 24 JANUARY 1991	Examiner AVEDIKIAN P.F.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons A : member of the same patent family, corresponding document	



EP 90 30 4734
Page 2

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A, P	--- EP-A-317641 (SAGAMI CHEMICAL RESEARCH CENTER) * the whole document *	2, 11-13	
A	--- EP-A-150126 (IMMUNEX CORPORATION) * the whole document *	2, 11-13	
A	--- CANCER RESEARCH vol. 45, no. 3, March 1985, USA pages 1337 - 1343; WHITE C. A.: "Two monoclonal antibodies selective for human mammary carcinoma" * abstract * -----	6-7	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
Place of search BERLIN		Date of completion of the search 24 JANUARY 1991	Examiner AVEDIKIAN P. F.
<div>CATEGORY OF CITED DOCUMENTS</div> <div>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</div> <div>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons ----- A : member of the same patent family, corresponding document</div>			